The company will be jointly financed by Daiichi Sankyo and Mitsubishi UFJ Capital. Technology is based on an antisense oligonucleotide (an ethylene-bridged nucleic acid) which acts by exxon skipping. The target period for clinical proof of concept is 4 years.

Daiichi Sankyo press release, February 14, 2013